Acrux (ASX:ACR) Forward PE Ratio: 0.00 (As of Jul. 09, 2026)


What is Acrux Forward PE Ratio?

Acrux ASX:ACR Forward PE Ratio is 0.00 as of Jul. 09, 2026. The stock has 6 warning signs investors should review. Among 354 Biotechnology companies, Acrux ranks worse than 282485.59% on this metric.

Acrux's Forward PE Ratio for today is 0.00.

Acrux's PE Ratio without NRI for today is 0.00.

Acrux's PE Ratio (TTM) for today is 0.00.

Acrux  (ASX:ACR) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Acrux Forward PE Ratio Related Terms

Acrux Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Acrux's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acrux Forward PE Ratio Chart

Acrux Annual Data
Trend 2016-06 2017-06
Forward PE Ratio
6.86 8.08

Acrux Semi-Annual Data
2015-12 2016-06 2016-12 2017-06
Forward PE Ratio 7.28 6.86 8.81 8.08

ASX:ACR vs VRTX, REGN, ALNY: Forward PE Ratio Comparison

For the Biotechnology subindustry, Acrux's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acrux Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrux's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Acrux's Forward PE Ratio falls into.


Acrux Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Acrux (ASX:ACR) has a Forward PE Ratio of 0.00 as of Jul. 09, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Acrux and its competitors. According to the industry distribution chart, Acrux ranks #999999 out of 354 companies in the Biotechnology industry.
Is Acrux's Forward PE Ratio too high?
Acrux's current Forward PE Ratio is 0.00. Based on the distribution chart, Acrux ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Acrux's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acrux ranks #999999 out of 354 companies for Forward PE Ratio. This places Acrux in the lower half of its industry. The industry median Forward PE Ratio is 22.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.12, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Acrux and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrux's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrux stock overvalued right now?
Based on GuruFocus' analysis, Acrux (ASX:ACR) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.03, compared to a current price of A$0.01 — trading 61.7% below its estimated fair value. The current Forward PE Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Acrux (ASX:ACR), the current Forward PE Ratio is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acrux Business Description

Other Exchanges ARUXF:USAFJY:Germany
Address 103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a dynamic Australian drug delivery specialist with expertise in developing and commercialising patient-preferred healthcare products for world-wide markets. Its talent creates value through the development and commercialisation of healthcare products using owned or acquired technologies. The group's products are patient preferred, protected by patent or other means, and use creative drug delivery.